Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 721 in Gilead Sciences

  1. IMS: US prescription drug spending jumped 13 percent in 2014Read the original story w/Photo

    20 hrs ago | The Daily Republic

    ... of them, Sovaldi, was launched at the end of 2013 yet was the top-selling drug last year. It brought maker Gilead Sciences Inc. $7.9 billion. "Sovaldi is a record-breaker in so many ways," Aitkin said, yet Gilead's successor drug launched last fall, ...

    Comment?

  2. Morningstar: Gilead Sciences To Grow Its Hepatitis C MarketRead the original story

    Yesterday | Benzinga

    Gilead Sciences Inc. 's is fighting competition for its hepatitis C drugs by expanding its access to patients, an analyst told Benzinga Friday. Morningstar's Karen Andersen said that despite AbbVie Inc. 's launch of its competing hepatitis treatment viekira pak late last year, Gilead is "doing a great job of hanging on to patient access" partly by discounting prices.

    Comment?

  3. This company doubled its Foster City office investment in 4 yearsRead the original story w/Photo

    Friday | Business Journal

    TA bought a 108,000-square-foot Foster City building for $28 million in 2011 and then got Gilead Sciences Inc., led by President John Milligan, to lease up the whole building last year. What happens when you lure a pharmaceutical giant to rent your entire building amid a red-hot real estate market? You double your money.

    Comment?

  4. Gilead Sciences Earns "A+" Credit RatingRead the original story

    Friday | AmericanBankingNews.com

    Gilead Sciences has earned an "A+" credit rating from analysts at Morningstar . The firm's "A+" rating suggests that the company is a low default risk.

    Comment?

  5. Gilead Is A Cash Generation MonsterRead the original story w/Photo

    Thursday Apr 16 | Seeking Alpha

    Despite starting to pay a dividend and generous share repurchases, the company will have more than twice the amount it spent for Pharmasset available for acquisitions. Gilead Sciences is not only the biggest of the Four Horsemen of Biotech by market capitalization, revenue, and earnings, but it is also the biggest generator of free cash flows.

    Comment?

  6. Why Gilead (Nasdaq: GILD) Is Still A Biotech Stock to BuyRead the original story w/Photo

    Thursday Apr 16 | Money Morning

    ... Follow his closely guarded techniques for making oversized gains in the most profitable sector in history. Gilead Sciences Inc. ( Nasdaq: GILD ) is facing criticism again this week for its highly priced Hepatitis C drug Sovaldi. The drug costs ...

    Comment?

  7. Fatty Liver Disease Therapeutic Development and Pipeline Market Review...Read the original story w/Photo

    Thursday Apr 16 | PRWeb

    ... Galmed International Ltd., Generon (Shanghai) Corporation Ltd., Genovate Biotechnology Co., LTD., Gilead Sciences, Inc., Huons Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Metabolic Solutions Development Company, LLC, Novartis AG Protalix ...

    Comment?

  8. Oil rally helps lift US stocksRead the original story

    Wednesday Apr 15 | The Standard

    ... capacity due to the strong dollar. Biotech companies rose, including Celgene (+2.1 percent) and Amgen and Gilead Sciences (both +1.7 percent). Other Nasdaq stocks that gained were Microsoft (+1.5 percent) and Cisco Systems (+1.6 percent). Bond ...

    Comment?

  9. Gilead Sciences Reminds Me Of Apple Circa June 2013Read the original story w/Photo

    Wednesday Apr 15 | Seeking Alpha

    After rising some 150% in less than three years, the stock of Gilead Sciences has been stuck in a relatively tight trading range for approximately nine months. The recent pause in the appreciation of shares is likely to be temporary given their cheap valuations, and the company's stranglehold on two key markets and increasing free cash flow.

    Comment?

  10. Prescription Drug Spending Jumped 13 Percent in 2014Read the original story w/Photo

    Wednesday Apr 15 | News Max

    ... of them, Sovaldi, was launched at the end of 2013 yet was the top-selling drug last year. It brought maker Gilead Sciences Inc. $7.9 billion. "Sovaldi is a record-breaker in so many ways," Aitkin said, yet Gilead's successor drug launched last fall, ...

    Comment?

  11. Prescription drug spending jumps 13 percent to record $374 billion in 2014Read the original story w/Photo

    Tuesday Apr 14 | UnionLeader.com

    ... treatments for hepatitis C - a cure that came with a wallop at the cash register. A 12-week treatment of Gilead Sciences Inc.'s breakthrough hepatitis C drug Sovaldi could cost more than $80,000 per patient. Gilead's drugs Sovaldi and Harvoni drove ...

    Comment?

  12. US Prescription Drug spending Jumped in 2014Read the original story w/Photo

    Tuesday Apr 14 | WBOC-TV Salisbury

    ... of them, Sovaldi, was launched at the end of 2013 yet was the top-selling drug last year. It brought maker Gilead Sciences Inc. $7.9 billion. "Sovaldi is a record-breaker in so many ways," Aitkin said, yet Gilead's successor drug launched last fall, ...

    Comment?

  13. Drug Costs Soar 13% In 2014Read the original story w/Photo

    Tuesday Apr 14 | Investor's Business Daily

    (NASDAQ: GILD ) new hep C drugs pressured prices too. ObamaCare advocates claim the law fueled slower drug-price growth, despite the worldwide trend starting before the reform. Others had pointed to the recession and slow recovery, a lack of new drugs and several blockbusters going off-patent.

    Comment?

  14. Analyst Wants Proof On Arrowhead Research's Hepatitis B DrugRead the original story

    Tuesday Apr 14 | Benzinga

    ... could reach the market until 2020. Competing treatments are under development by privately held Replicor, Gilead Sciences, Inc. (NASDAQ: GILD ) and Tekmira Pharmaceuticals Corp (NASDAQ: TKMR ), with the best potential cure stemming from ...

    Comment?

  15. IMS: US prescription drug spending jumped 13 pct. in 2014Read the original story w/Photo

    Tuesday Apr 14 | Worcester Telegram & Gazette

    ... of them, Sovaldi, was launched at the end of 2013 yet was the top-selling drug last year. It brought maker Gilead Sciences Inc. $7.9 billion. "Sovaldi is a record-breaker in so many ways," Aitkin said, yet Gilead's successor drug launched last fall, ...

    Comment?

  16. Prescription drug spending surged 13 percent in 2014Read the original story w/Photo

    Tuesday Apr 14 | Marin Independent Journal

    ... of them, Sovaldi, was launched at the end of 2013 yet was the top-selling drug last year. It brought maker Gilead Sciences $7.9 billion. "Sovaldi is a record-breaker in so many ways," Aitkin said, yet Foster City-based Gilead's successor drug ...

    Comment?

  17. Prescription drug spending jumps 13% to record $374 billion in 2014Read the original story w/Photo

    Tuesday Apr 14 | Los Angeles Times

    A 12-week treatment of Gilead Sciences' breakthrough hepatitis C drug Sovaldi, above, could cost more than $80,000 per patient. A 12-week treatment of Gilead Sciences' breakthrough hepatitis C drug Sovaldi, above, could cost more than $80,000 per patient.

    Comment?

  18. U.S. prescription drug spending rose 13 percent in 2014: IMS reportRead the original story

    Monday Apr 13 | WNFL-AM Green Bay

    ... of the IMS Institute for Healthcare Informatics, which compiled the report. New hepatitis C treatments from Gilead Sciences Inc that virtually guarantee a cure for the liver-destroying virus, with few side effects, led more than 161,000 patients to ...

    Comment?

  19. Spending on prescription drugs soared in 2014Read the original story

    Monday Apr 13 | The Times-Tribune

    ... of them, Sovaldi, was launched at the end of 2013 yet was the top-selling drug last year. It brought maker Gilead Sciences Inc. $7.9 billion. "Sovaldi is a record-breaker in so many ways," Aitkin said, yet Gilead's successor drug launched last fall, ...

    Comment?

  20. 7 Trends Drug Investors Should KnowRead the original story

    Monday Apr 13 | Benzinga

    ... the information gathered by market researcher IMS Health Holdings Inc (NYSE: IMS ) in a note Monday. Gilead Sciences, Inc. (NASDAQ: GILD )'s Harvoni prescriptions were off 3.1 percent and Liang expects second-quarter sales of the hepatitis C ...

    Comment?